Lakefront Biotherapeutics (LKFT) Amortization (2017 - 2018)
Lakefront Biotherapeutics (LKFT) reported Amortization of $24.0 million for Q3 2018, up 185.59% year-over-year from $8.4 million in Q3 2017, and up 181.4% quarter-over-quarter from -$29.4 million in Q2 2018.
Lakefront Biotherapeutics (LKFT) Amortization (2017 - 2018) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 2 years of Amortization data on file, last reported at $24.0 million in Q3 2018.
- Amortization for Q3 2018 came in at $24.0 million, up 185.59% year-over-year; the trailing twelve-month figure through Sep 2018 was -$42.2 million (changed N/A YoY), and the FY2017 annual result was -$8.7 million, changed N/A from the prior year.
- Amortization rose to $24.0 million in Q3 2018 per LKFT's latest filing, from -$29.4 million in the prior quarter.
- Over five years, Amortization peaked at $24.0 million in Q3 2018 and troughed at -$29.4 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 23.96 Mn |
| Sep 30, 2018 | 23.96 Mn |
| Jun 30, 2018 | -29.43 Mn |
| Jun 30, 2018 | -29.43 Mn |
| Dec 31, 2017 | -8.73 Mn |
| Dec 31, 2017 | -8.73 Mn |
| Sep 30, 2017 | -27.99 Mn |
| Sep 30, 2017 | -27.99 Mn |